Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
NCT04649229Phase 4Completed
- Sponsor
- Yale University
- Start
- May 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aprepitant in heart failure (HF) (4 arms), sponsored by Yale University. Primary endpoints: Max Change in Mean Arterial Pressure at 6 hours and Urine Sodium Excretion at 6 hours. Started May 2021; status: completed.
02
Drugs
aprepitant
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04649229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649229.